Hematologic Oncology

Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, discusses the status of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

Daniel J. Landsburg, MD, discusses the management of patients with double-hit lymphoma who have achieved remission.

Ronald S. Go, MD, provides perspective on thrombotic microangiopathy and paroxysmal nocturnal hemoglobinuria, including how community physicians can properly diagnose and treat them.

BGB-3111, a second-generation BTK inhibitor, is being tested in patients with refractory B-cell lymphoid malignancies in an effort to determine whether the novel oral small molecule is a viable therapeutic option and to better understand its pharmacologic properties.

Sameer A. Parikh, MD, discusses how the International Prognostic Index has assisted physicians with their patients who have CLL, the optimal sequencing of therapies, and other emerging molecular targets in this disease.

Kebede H. Begna, MD, assistant professor of Medicine, Mayo Clinic, discusses some of the recent advancements in the field of myeloproliferative neoplasms (MPNs).

Aref Al-Kali, MD, discusses some of the recent advancements, exciting ongoing trials, and largest unanswered questions in AML.

Results from the phase III SABRINA trial showed that subcutaneous administration of rituximab produced nearly identical response rates and toxicity as IV administration in the first-line treatment of follicular lymphoma.

Ellen K. Ritchie, MD, highlights current and emerging novel treatments, and the possibility of using immunotherapy to treat patients with systemic mastocytosis, advanced symptomatic hypereosinoophic disorder, myelofibrosis, and chronic myelomonocytic leukemia

John P. Leonard, MD, discusses advancements across hematologic malignancies and pivotal trial data he is anticipating at the 2017 ASCO Annual Meeting.

Sarah Rutherford, MD, John P. Leonard, M.D./Gwirtzman Family Research Scholar in Lymphoma , assistant professor of medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the classification and prevalence of double-hit and double-expressor lymphomas.

Gail J. Roboz, MD, discusses the recent FDA approval of midostaurin and what else is emerging in the treatment landscape in AML.

Lisa Giulino Roth, MD, assistant professor of Pediatrics in Medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treating adolescent and young adult patients with Hodgkin lymphoma.

The first cerebral edema death in the ZUMA-1 CAR T-cell therapy trial was disclosed today by Kite Pharma on a conference call with investors announcing the company’s first quarter financial results.

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with chronic lymphocytic leukemia who have developed Richter’s transformation.

JUNO Therapeutics announced that it hopes to accelerate its process for developing CAR T cells from weeks to just 2 days.

Sattva S. Neelapu, MD, discusses the ZUMA-1 trial and the potential impact of these results on patients with non-Hodgkin lymphoma.